The demand for oligonucleotides and mRNA has rocketed over the last year, most notably in the rush for vaccines in response to COVID-19.
With so much development in so little time, along with under-developed regulations and equipment to support, what are the best strategies for scalable manufacturing of mRNA and oligonucleotides?
This ebook is a collection of insights shared by experts from the likes of Moderna, Asahi Kasei Bioprocess America and the European Pharma Oligonucleotide Consortium.
In exclusive interviews, whitepapers and presentations from the latest TIDES events, we highlight strategies for rapid deployment of mRNA manufacturing, oligo synthesis, navigating regulatory guidance and scaling up manufacturing equipment.
Explore or download the interactive eBook by clicking on the image above or here.
Contents of the eBook include:
- mRNA Manufacturing for Fast and Flexible Vaccine Development: A presentation by Katarina Stenklo, Enterprise Solutions Commercial Activation Leader at Cytiva.
- Mastering the Fundamentals of Oligo Development: A whitepaper by Steve Foy, Product Marketing Manager at Asahi Kasei Bioprocess America.
- Rapid Deployment of a Messenger RNA Vaccine for Pandemic Response: A presentation by Don Parsons, PhD, VP, Early Technical Development & LNP Process Development at Moderna Therapeutics, Inc.
- CMC Regulatory Challenges in the Development of Oligonucleotide Therapeutics: A selection of insights presented by Susanne Kindermann, Technical Regulatory Manager at Roche.
- Optimizing oligonucleotide manufacturing with Asahi Kasei: Market growth, key challenges and scaling up: an interview with Scott Merz, Business Development Manager at Asahi Kasei Bioprocess America, Inc.
- DNA Synthesis for mRNA Therapeutics – How to Ensure Good Results by Choosing the Right DNA: Lessons on optimizing DNA design, watermarks and synthesis shared by Dr. Axel Trefzer, R&D Leader at Thermo Fisher Scientific.
Explore or download the interactive eBook by clicking on the image above or here.